Baseline characteristics for all 80 randomised patients
| Characteristics | Sequence | |||
|---|---|---|---|---|
| First amantadine, then placebo | First placebo, then amantadine | |||
| MRC, Medical Research Counsil; GBS, Guillain-Barré syndrome; FSS, Fatigue Severity Scale. All baseline characteristics were measured at visit 1. Ranges: *0 to 60; †0 to 6; ‡1 to 7. | ||||
| Sex, n | ||||
| Female | 19 | 21 | ||
| Male | 21 | 19 | ||
| Median age at start of study, years (range) | 47.5 (19 to 77) | 52 (24 to 82) | ||
| Median duration after diagnosis, years (range) | 3.8 (0.5 to 13.1) | 2.6 (0.5 to 15) | ||
| MRC sumscore distribution*, n (%) | ||||
| 48–57 | 4 (5%) | 8 (10%) | ||
| 58–59 | 12 (15%) | 7 (9%) | ||
| 60 | 24 (30%) | 25 (31%) | ||
| GBS disability score distribution,† n (%) | ||||
| 1 | 30 (38%) | 26 (33%) | ||
| 2 | 7 (9%) | 13 (16%) | ||
| 3 | 3 (4%) | 1 (1%) | ||
| FSS score‡, median (range) | 5.9 (5.1 to 7.0) | 6.0 (5.0 to 7.0) | ||